Charmacy Pharmaceutical Co., Ltd.
Symbol: 2289.HK
HKSE
10.6
HKDMarktpreis heute
26.5108
P/E-Verhältnis
-0.6536
PEG-Verhältnis
1.14B
MRK Kapital
- 0.08%
DIV Rendite
Charmacy Pharmaceutical Co., Ltd. (2289-HK) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 634.2 | 503.8 | 641.8 | |||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 11.1 | 11.6 | |||||||||||
balance-sheet.row.net-receivables | 0 | 965.4 | 865.3 | 731.3 | |||||||||||
balance-sheet.row.inventory | 0 | 775.8 | 586.9 | 509.2 | |||||||||||
balance-sheet.row.other-current-assets | 0 | 436.6 | 506.4 | 356 | |||||||||||
balance-sheet.row.total-current-assets | 0 | 2812 | 2462.4 | 2238.2 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 328.5 | 294.1 | 348.4 | |||||||||||
balance-sheet.row.goodwill | 0 | 6 | 6 | 6 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 76.7 | 80.9 | 143 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 82.7 | 86.9 | 149.1 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 374.7 | 489.3 | |||||||||||
balance-sheet.row.tax-assets | 0 | 7.4 | 6.2 | 8.2 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 17 | -381 | -497.5 | |||||||||||
balance-sheet.row.total-non-current-assets | 0 | 435.7 | 381 | 497.5 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 22.6 | 27.4 | |||||||||||
balance-sheet.row.total-assets | 0 | 3247.7 | 2865.9 | 2763.1 | |||||||||||
balance-sheet.row.account-payables | 0 | 659.1 | 876.8 | 809.8 | |||||||||||
balance-sheet.row.short-term-debt | 0 | 1531.1 | 1390 | 1512.6 | |||||||||||
balance-sheet.row.tax-payables | 0 | 56 | 94.2 | 44.6 | |||||||||||
balance-sheet.row.long-term-debt-total | 0 | 30.4 | 15.8 | 86.9 | |||||||||||
Deferred Revenue Non Current | 0 | -0.6 | 0 | 0.3 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 0 | 2.5 | 1378.8 | 1349.2 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 31 | 15.8 | 86.9 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 13.2 | |||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 37 | 15.8 | 15.5 | |||||||||||
balance-sheet.row.total-liab | 0 | 2649.8 | 2271.4 | 2259 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0 | 108 | 108 | 108 | |||||||||||
balance-sheet.row.retained-earnings | 0 | 181.2 | 207.5 | 117.1 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 279 | 1 | 1 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 29.7 | 278 | 278 | |||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 597.8 | 594.5 | 504.1 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 3247.7 | 2865.9 | 2763.1 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 0 | 597.8 | 594.5 | 504.1 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||
Total Investments | 0 | 0 | 11.1 | 11.6 | |||||||||||
balance-sheet.row.total-debt | 0 | 1561.5 | 1405.8 | 1611.9 | |||||||||||
balance-sheet.row.net-debt | 0 | 927.3 | 913.1 | 981.8 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 90.4 | 23.2 | 40.6 | ||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 28.8 | 32 | 24.6 | ||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.change-in-working-capital | 0 | -300.2 | 20.9 | -227.9 | ||||||||||
cash-flows.row.account-receivables | 0 | -222.5 | -54.8 | -158 | ||||||||||
cash-flows.row.inventory | 0 | -77.7 | 75.8 | -69.8 | ||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-non-cash-items | 0 | 225 | -95.7 | 293.8 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -8.6 | -25 | -52 | ||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | -2.9 | ||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-investing-activites | 0 | 80.4 | 0.6 | 0.1 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 71.8 | -24.4 | -54.8 | ||||||||||
cash-flows.row.debt-repayment | 0 | -1074.5 | -824.1 | -888.6 | ||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.dividends-paid | 0 | -28.4 | -52.5 | -56.5 | ||||||||||
cash-flows.row.other-financing-activites | 0 | 911.7 | 951 | 942.5 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -191.2 | 74.4 | -2.7 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.net-change-in-cash | 0 | -75.4 | 30.5 | 73.6 | ||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 68.9 | 144.2 | 113.8 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 144.2 | 113.8 | 40.1 | ||||||||||
cash-flows.row.operating-cash-flow | 0 | 44.1 | -19.5 | 131.1 | ||||||||||
cash-flows.row.capital-expenditure | 0 | -8.6 | -25 | -52 | ||||||||||
cash-flows.row.free-cash-flow | 0 | 35.5 | -44.6 | 79.1 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 4403.6 | 4175.3 | 3793.6 | |||||||||||
income-statement-row.row.cost-of-revenue | 0 | 4110.9 | 3906.7 | 3559.5 | |||||||||||
income-statement-row.row.gross-profit | 0 | 292.7 | 268.6 | 234.1 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | -0.1 | -0.4 | -0.1 | |||||||||||
income-statement-row.row.operating-expenses | 0 | 178 | 116.1 | 163.4 | |||||||||||
income-statement-row.row.cost-and-expenses | 0 | 4288.9 | 4022.8 | 3722.9 | |||||||||||
income-statement-row.row.interest-income | 0 | 4.3 | 30.5 | 37.7 | |||||||||||
income-statement-row.row.interest-expense | 0 | 40.8 | 35.1 | 41.5 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -41.2 | 28.6 | -41.4 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | -0.1 | -0.4 | -0.1 | |||||||||||
income-statement-row.row.total-operating-expenses | 0 | -41.2 | 28.6 | -41.4 | |||||||||||
income-statement-row.row.interest-expense | 0 | 40.8 | 35.1 | 41.5 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 26.5 | 25.7 | 29.1 | |||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 0 | 66.2 | 93.5 | 74.4 | |||||||||||
income-statement-row.row.income-before-tax | 0 | 67.4 | 122.1 | 33 | |||||||||||
income-statement-row.row.income-tax-expense | 0 | 16.1 | 31.7 | 9.8 | |||||||||||
income-statement-row.row.net-income | 0 | 51.3 | 90.5 | 23.2 |
Häufig gestellte Frage
Wie hoch ist die Charmacy Pharmaceutical Co., Ltd. (2289.HK) Gesamtvermögen?
Charmacy Pharmaceutical Co., Ltd. (2289.HK) Gesamtvermögen ist 3247655876.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist N/A.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.066.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist -2.398.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist 0.012.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist 0.025.
Was ist der Charmacy Pharmaceutical Co., Ltd. (2289.HK) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist 51344725.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 1561459369.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 178011533.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 0.000.